Metraipolis › archive › dc_39e2170bcc88

[Glofitamab for relapsed/refractory B-cell lymphoma: analysis of efficacy and influencing factors] — Europe PMC PMID:42409737

Source
Europe PMC (chi)
Original
https://europepmc.org/article/MED/42409737
DOI
10.3760/cma.j.cn121090-20260104-00002
License (as archived)
solo-consultazione
Archived
2026-11-02T21:58:42.523Z
SHA-256 of the archived text
f7acc06a924b65c7bf660151fae2b77cc3ed78f53c48299c9477807b11c8d6a7
Stable URL of this page
https://metraipolis.com/documento/dc_39e2170bcc88

How to cite

[Glofitamab for relapsed/refractory B-cell lymphoma: analysis of efficacy and influencing factors] — Europe PMC PMID:42409737 — Europe PMC (chi), https://europepmc.org/article/MED/42409737 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_39e2170bcc88 (Metraipolis archive dc_39e2170bcc88, sha256 f7acc06a924b65c7bf660151fae2b77cc3ed78f53c48299c9477807b11c8d6a7)
BibTeX
@misc{dc39e2170bcc88,
  title = {[Glofitamab for relapsed/refractory B-cell lymphoma: analysis of efficacy and influencing factors] — Europe PMC PMID:42409737},
  howpublished = {Europe PMC (chi)},
  url = {https://europepmc.org/article/MED/42409737},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_39e2170bcc88; sha256 f7acc06a924b65c7bf660151fae2b77cc3ed78f53c48299c9477807b11c8d6a7},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42409737. Agents can read the archived copy with the MCP tool read_document.